Table 1 Baseline characteristics of patients based on NY-ESO-1 and p53 antibody status.
NY-ESO-1 antibody (−) (n = 875) | NY-ESO-1 antibody (+) (n = 126) | P value | p53 antibody (−) (n = 820) | p53 antibody (+) (n = 181) | P value | |
|---|---|---|---|---|---|---|
Age, years | 72 (34–90) | 74 (41–90) | 0.012 | 72 (34–90) | 73 (40–90) | 0.59 |
Gender | ||||||
Male | 599 (68.5%) | 105 (83.3%) | 0.001 | 564 (68.8%) | 140 (73.3%) | 0.022 |
Female | 276 (31.5%) | 21 (16.7%) | 256 (31.2%) | 41 (22.7%) | ||
cT | ||||||
3 | 430 (49.1%) | 60 (47.6%) | 0.75 | 406 (49.5%) | 84 (46.4%) | 0.45 |
4 | 445 (50.9%) | 66 (52.4%) | 414 (50.5%) | 97 (53.6%) | ||
cN | ||||||
0 | 330 (37.7%) | 28 (22.2%) | 0.006 | 298 (36.3%) | 60 (33.1%) | 0.87 |
1 | 259 (29.6%) | 43 (34.1%) | 244 (29.8%) | 58 (32.0%) | ||
2 | 210 (24.0%) | 38 (30.2%) | 202 (24.6%) | 46 (25.4%) | ||
3 | 76 (8.7%) | 17 (13.5%) | 76 (9.3%) | 17 (9.4%) | ||
cStage | ||||||
II | 439 (50.2%) | 47 (37.3%) | 0.026 | 401 (48.9%) | 85 (47.0%) | 0.853 |
III | 407 (46.5%) | 74 (58.7%) | 392 (47.8%) | 89 (49.2%) | ||
IV | 29 (3.3%) | 5 (4.0%) | 27 (3.3%) | 7 (3.9%) | ||
Tumor location | ||||||
Lower | 341 (39.0%) | 42 (36.5%) | 0.058 | 312 (38.0%) | 71 (39.2%) | 0.71 |
Middle | 322 (36.8%) | 41 (33.3%) | 302 (36.8%) | 61 (33.7%) | ||
Upper | 212 (24.2%) | 43 (30.2%) | 206 (25.1%) | 49(27.1%) | ||
Histological typea | ||||||
Differentiated | 396 (45.3%) | 73 (57.9%) | 0.068 | 378 (46.1%) | 91 (50.3%) | 0.60 |
Undifferentiated | 383 (43.8%) | 42 (33.3%) | 356 (43.4%) | 69 (38.1%) | ||
Others | 45 (5.1%) | 5 (4.0%) | 41 (5.0%) | 9 (5.0%) | ||
No dissection | 51 (5.8%) | 6 (4.8%) | 45 (5.5%) | 12 (6.6%) | ||
Neoadjuvant chemotherapy | ||||||
No | 783 (89.5%) | 115 (91.3%) | 0.54 | 738 (90.0%) | 160 (88.4%) | 0.52 |
Yes | 92 (10.5%) | 11 (8.7%) | 82 (10.0%) | 21 (11.6%) | ||
Surgical curability | ||||||
R0 | 680 (77.7%) | 98 (77.8%) | 0.74 | 647 (78.9%) | 131 (72.4%) | 0.24 |
R1 | 95 (10.9%) | 14 (11.1%) | 83 (10.1%) | 26 (14.4%) | ||
R2 | 98 (11.2%) | 13 (10.3%) | 88 (10.7%) | 23 (12.7%) | ||
No operation | 2 (0.2%) | 1 (0.8%) | 2 (0.2%) | 1 (0.6%) | ||
pTb | ||||||
0 | 6 (0.7%) | 1 (0.8%) | 0.006 | 7 (0.9%) | 0 (0%) | 0.31 |
1 | 82 (10.0%) | 6 (5.0%) | 77 (9.9%) | 11 (6.5%) | ||
2 | 93 (11.3%) | 25 (20.8%) | 92 (11.9%) | 26 (15.4%) | ||
3 | 299 (36.3%) | 51 (42.5%) | 285 (36.8%) | 65 (38.5%) | ||
4 | 344 (41.7%) | 37 (30.8%) | 314 (40.5%) | 67 (39.6%) | ||
pNb | ||||||
0 | 267 (32.4%) | 28 (23.3%) | 0.065 | 243 (31.4%) | 52 (30.8%) | 0.80 |
1 | 150 (18.2%) | 25 (20.8%) | 146 (18.8%) | 29 (17.2%) | ||
2 | 160 (19.4%) | 19 (15.8%) | 149 (19.2%) | 30 (17.8%) | ||
3 | 247 (30.0%) | 48 (40.0%) | 237 (30.6%) | 58 (34.3%) | ||
pStageb | ||||||
0 | 6 (0.7%) | 1 (0.8%) | 0.82 | 7 (0.9%) | 0 (0%) | 0.15 |
I | 124 (15.0%) | 13 (10.8%) | 116 (15.0%) | 21 (12.4%) | ||
II | 242 (29.4%) | 37 (30.8%) | 225 (29.0%) | 54 (32.0%) | ||
III | 319 (38.7%) | 48 (40.0%) | 309 (39.9%) | 58 (34.3%) | ||
IV | 133 (16.1%) | 21 (17.5%) | 118 (15.2) | 36 (21.3%) | ||
Adjuvant chemotherapy | ||||||
No | 783 (89.5%) | 115 (91.3%) | 0.54 | 738 (90.0%) | 160 (88.4%) | 0.52 |
Yes | 92 (10.5%) | 11 (8.7%) | 82 (10.0%) | 21 (11.6%) | ||
